Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
See All Experts
Published in Oncology

Journal Scan / Research · April 30, 2023

Belzutifan Plus Cabozantinib in Patients With Advanced ccRCC Previously Treated With Immunotherapy

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

The Lancet Oncology
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Lancet Oncol 2023 Mar 31;[EPub Ahead of Print], TK Choueiri, DF McDermott, J Merchan, TM Bauer, R Figlin, EI Heath, MD Michaelson, E Arrowsmith, A D'Souza, S Zhao, A Roy, R Perini, D Vickery, SS Tykodi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated